Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 10/20 | 0.76 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.76 |
| ▸ | GAA | P10253 | 2/20 | 0.76 |
| ▸ | GFER | P55789 | 1/20 | 0.76 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.72 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.72 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.67 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 2/20 | 0.53 |
| ▸ | CDC7 | O00311 | 1/20 | 0.53 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL822697 | 0.95 | MEN1 (0.84) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL2199730 | 0.91 | MCHR1 (0.82) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL2199726 | 0.91 | MCHR1 (0.82) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL822685 | 0.89 | MEN1 (0.82) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL4352297 | 0.88 | MEN1 (0.78) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL4352294 | 0.88 | MEN1 (0.78) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL4355372 | 0.88 | GRIN1 (0.78) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL4355367 | 0.88 | GRIN1 (0.78) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL4348152 | 0.88 | MEN1 (0.76) | MEN1KMT2AGAAGFERGRIN1 | |
| SCHEMBL4348827 | 0.88 | MEN1 (0.76) | MEN1KMT2AGAAGFERGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198891-B2 | Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase | NEW YORK UNIVERSITY (US) | 2015-12-01 | — | — | US | disclosed |
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | NEW YORK UNIVERSITY (US) | 2011-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288083-A1 | METHOD OF TREATING CANCER BY INHIBITION OF PROTEIN KINASE-LIKE ENDOPLASMIC RETICULUM PROTEIN KINASE | ERN1, ERN2, EEF2K | MEN1 3488/4885KMT2A 3197/4885GAA 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.